# Johnson & Johnson (NYSE: JNJ) Q2 2025 Earnings Report
*Release Date: July 16, 2025*
Johnson & Johnson (J&J) reported its second-quarter results for 2025, highlighting strong sales and earnings performance, along with strategic advancements in its product pipeline. Below are the key financial metrics and operational insights:
### Financial Summary
– **Sales & Earnings**:
– Reported sales rose by **5.8%** to **$23.7 billion**, up from **$22.4 billion** the previous year.
– Net earnings increased by **18.2%** to **$5.5 billion** from **$4.7 billion** previously.
– Diluted earnings per share (EPS) reached **$2.29**, a growth of **18.7%** from **$1.93** in Q2 2024.
– **Non-GAAP Measurements**:
– Operational sales grew by **4.6%**, while adjusted operational sales increased by **3.0%** year-over-year.
– Adjusted net earnings showed a slight decrease of **2.1%** to **$6.7 billion** compared to **$6.8 billion** in Q2 2024.
– Adjusted diluted EPS declined by **1.8%** to **$2.77** from **$2.82**.
– **Free Cash Flow**: Estimated at approximately **$6.2 billion**, a decrease from **$7.5 billion** year-on-year.
### Regional Sales Performance
– **United States**:
– Sales increased by **7.8%** to **$13.5 billion** from **$12.6 billion** last year.
– Operational growth stood at **7.8%**, while adjustments showed a **5.0%** increase.
– **International**:
– Sales rose by **3.2%** to **$10.2 billion**, compared to **$9.9 billion** in 2024.
– Operational growth was modest at **0.6%**, with currency effects contributing **2.6%**.
### Segment Sales Overview
– **Innovative Medicine**:
– Sales grew by **4.9%** to **$15.2 billion**; operational growth was lower at **3.8%**.
– Key growth contributors included DARZALEX, CARVYKTI, and others.
– **MedTech**:
– Sales expanded by **7.3%** to **$8.5 billion**, with significant operational growth of **6.1%**.
– Growth was driven by electrophysiology and wound closure products.
### Outlook and Guidance for 2025
– J&J raised its full-year sales guidance for reported sales growth to approximately **5.4%** at the midpoint, adjusted from a previous estimate.
– Full-year EPS guidance increased by **$0.25** to **$10.85**.
### Notable Announcements and Strategic Developments
– Approval of the product IMAAVY for myasthenia gravis marked a significant addition to J&J’s product lineup.
– A commitment to expanding novel proposals across multiple therapeutic areas, notably cancer and cardiovascular diseases.
– Continuous investment in product development, illustrated by several ongoing clinical trials and submitted applications for vital medications.
### Dividend and Share Repurchase
– Johnson & Johnson has not disclosed any new quarterly dividend declarations or share repurchase initiatives in the quarter.
### Conclusion
The Q2 2025 results underscore Johnson & Johnson’s robust financial health and strategic initiatives across its business segments. Despite minor declines in adjusted metrics, the company showcases adaptability and growth potential, especially through its innovative pipeline and improved sales forecasts.
